Amparo Hernándiz Martinez

Title: Amparo Hernándiz Martinez: Innovator in Cardiotoxicity Prediction

Introduction

Amparo Hernándiz Martinez is a notable inventor based in Valencia, Spain. He has made significant contributions to the field of medical research, particularly in predicting cardiotoxicity risk in cancer patients undergoing anthracyclines chemotherapy. His innovative approach utilizes a specific set of circulating microRNAs as biomarkers for this critical health concern.

Latest Patents

Amparo Hernándiz Martinez holds a patent for an invention titled "Predicting cardiotoxicity risk in cancer patients receiving anthracyclines chemotherapy." This invention refers to an in vitro method for predicting the risk of cardiotoxicity based on the expression levels of a combination of 10 circulating miRNAs. These include miRNA 16-5p, miRNA 22-3p, miRNA 30b-5p/30c-5p, miRNA 92b-3p, miRNA 148a-3p, miRNA-150-5p, miRNA-192-5p, miRNA 215-5p, miRNA 486-3p/486-5p, and miRNA-4732-3p. The invention also encompasses a method for preventing cardiotoxicity by modulating the expression levels of these miRNAs.

Career Highlights

Throughout his career, Amparo Hernándiz Martinez has worked with esteemed institutions such as the Fundación Para La Investigación Del Hospital Universitario La Fe De La Comunidad Valenciana and Maastricht University. His work has been pivotal in advancing the understanding of cardiotoxicity in cancer treatment.

Collaborations

Amparo has collaborated with notable colleagues, including David Hervàs Marin and Ana Santaballa Beltràn, who have contributed to his research endeavors.

Conclusion

Amparo Hernándiz Martinez is a pioneering inventor whose work in predicting cardiotoxicity risk has the potential to significantly improve patient outcomes in cancer treatment. His innovative methods and collaborations highlight the importance of research in enhancing medical practices.